U.S. Markets close in 28 mins
  • S&P 500

    3,230.63
    -6.29 (-0.19%)
     
  • Nasdaq

    10,610.94
    -22.05 (-0.21%)
     
  • Russell 2000

    1,454.75
    +3.30 (+0.23%)
     
  • Crude Oil

    40.14
    +0.21 (+0.53%)
     
  • Gold

    1,866.10
    -2.30 (-0.12%)
     
  • Silver

    22.96
    -0.15 (-0.63%)
     
  • EUR/USD

    1.1669
    +0.0007 (+0.0583%)
     
  • 10-Yr Bond

    0.6660
    -0.0100 (-1.48%)
     
  • Vix

    28.73
    +0.15 (+0.52%)
     
  • GBP/USD

    1.2736
    +0.0010 (+0.0790%)
     
  • BTC-USD

    10,626.39
    +376.92 (+3.68%)
     
  • CMC Crypto 200

    216.47
    +7.52 (+3.60%)
     
  • FTSE 100

    5,822.78
    -76.48 (-1.30%)
     
  • Nikkei 225

    23,087.82
    -258.67 (-1.11%)
     

BOQI International Medical Announces First Quarter 2020 Financial Results

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- BOQI International Medical Inc. (BIMI) (“BIMI” or the “Company”) today announced its financial results for the fiscal quarter ended March 31, 2020.

"The first quarter was a good start for our healthcare business. Despite the impact caused by the pandemic, we completed the acquisition of Guanzan as planned. In the second quarter we raised funds through the sale of convertible notes and divested our legacy energy business. These actions raised funds for our working capital needs and for further expansion," said Mr. Tiewei Song, Chief Executive Officer and President of BOQI International Medical Inc. "As we enter into the third quarter, we intend to continue to expand our market presence and drive innovation in our new telemedicine business. I'm proud of the progress we've made and I'm confident we will continue to raise the bar on what's possible during the rest of 2020."

Revenues

Revenues from the Company’s continuing operations for the three months ended March 31, 2020 and 2019 were $426,898 and $0, respectively. The revenues for the three months ended March 31, 2020 were primarily attributable to the revenues of the Company’s newly acquired Guanzan Group, a distributor of medicine and medical devices that was acquired on March 18, 2020. These revenues reflect the sales of the wholesale medicine and wholesale medical devices segments of the Guanzan Group since their acquisition on March 18, 2020. Revenues from the wholesale medicine and the wholesale medical devices segments for the three months ended March 31, 2020 were $248,027 and $166,557, respectively. The stand-alone revenues of the Guanzan Group for the three months ended March 31, 2020 were $1,706,396. There were no revenues from continuing operations for the three months ended March 31, 2019, because the business operation of the NF Group was reclassified as a discontinued operation and the Company’s current continuing operations were acquired after March 31, 2019.

Cost of Revenues

Cost of revenues from the Company’s continuing operations for the three months ended March 31, 2020 and 2019 were $461,782 and $0, respectively. Because of the lockdown policy that was instituted in China in the first quarter of 2020, the Company’s retail pharmacy stores made almost no sales which resulted in a large portion of the Company’s inventory to expire unsold.

For the three months ended March 31, 2020, the cost of revenues of the Company’s retail pharmacy segment was $129,483, which included an inventory write-off of $119,342. For the three months ended March 31, 2020, the cost of revenues of the Company’s wholesale medical devices segment was $199,036 and the cost of revenues of the Company’s wholesale medicine segment was $133,263.

Operating Expenses

Operating expenses consist mainly of auditing and legal service fees, other professional service fees, directors’ and officers’ compensation expenses, meeting and promotional expenses, changes in fair value of derivative liabilities, depreciation and amortization of items not associated with production, office rental fee and utilities.

Operating expenses from continuing operations were $1,751,453 for the three months ended March 31, 2020 as compared to $122,614 for the same period in 2019, an increase of $1,628,839, or 1,328%. The increase is primarily attributable to the operating expenses of Boqi Zhengji of $345,431 and the Guanzan Group of $47,511, the amortization of the discount relating to the convertible notes issued in 2019 of $294,958, changes in fair value of derivative liabilities of $399,022 and an increase of about $540,000 of general operating expenses which primarily resulted from the increase in auditing and legal expenses and officers’ salary.

Operating expenses of the retail pharmacy segment for the three months ended March 31, 2020 included $256,511 of amortization of the intangible assets recognized in the acquisition of Boqi Zhengji. The operating expenses of the wholesale medicine and wholesale medical devices segments for the three months ended March 31, 2020 were $34,761 and $12,750, respectively.

Net Loss

Net loss from continuing operations was $1,827,705 for the three months ended March 31, 2020 as compared to a net loss of $122,614 for the same period in 2019, an increase of $1,705,091, or 1,391%.

The operations of the NF Group are classified as discontinued operations. Loss from the discontinued operation was $374,486 for the three months ended March 31, 2020 compared to a loss of $419,834 for the same period of 2019. The decrease of $45,348, or 11%, was mainly due to lower depreciation and amortization costs in the current period.

Recent Events

The COVID-19 outbreak and mitigation efforts in China have materially impacted our operations. At the beginning of February 2020, the Chinese government issued a quarantine order, which lasted for more than two months in many parts of the country, where everyone had to stay at home. During February and March, all of our administrative functions had to be performed remotely. Not until the beginning of April, did we start to have a small skeleton crew in our offices. Because of the pandemic, we also suffered a significant reduction.in sales. Because of the Chinese government’s lockdown order, our customer traffic dropped greatly. Certain of our popular and high profit margin products could not be sold due to the governmental restrictive orders, which also resulted in the expiration of a large quantity of our medicines that are otherwise in high demand in the winter season.

We have incurred additional costs to ensure we meet the needs of our customers, including providing additional cleaning materials for our stores and other facilities. We expect to continue to incur additional costs, which may be significant, as we continue to implement operational changes in response to this pandemic. COVID-19 has also caused supply chain disruption which has resulted in higher supply chain costs to replenish inventories in our stores and distribution center and such increased costs in our supply chain are likely to continue. Furthermore, we have experienced restricted stock availability in a number of key categories and while we have significantly increased our purchases across many key categories, we may face delays or difficulty sourcing certain products which could negatively impact us. We cannot be sure when this situation will improve.

Liquidity and Capital Resources

At March 31, 2020, the Company had cash of $175,865 and negative working capital of $6,008,248 as compared to cash of $36,363 and working capital of $500,765 at December 31, 2019. As of March 31, 2020, the Company had an accumulated deficit of $13 million and negative working capital of $6 million. In addition, the Company continues to generate operating losses and has limited cash flow from its continuing operations. Management believes these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months.

The continuation of the Company as a going concern through the next twelve months is dependent upon (1) the continued financial support from its stockholders or external financing, and (2) further implement management’s business plan to extend its operations and generate sufficient revenues and cash flow to meet its obligations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s unaudited condensed financial statements for the quarter ended March 31, 2020 do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties.

Subsequent Events

On May 18, 2020, the Company entered into an agreement with two institutional investors to sell a new series of senior secured convertible notes in a private placement in the aggregate principal amount of $6,550,000 having an aggregate original issue discount of 19.85%, and ranking senior to all outstanding and future indebtedness of the Company. On June 2, 2020, two convertible notes in an aggregate original principal amount of $4,450,000 were issued to the institutional investors in consideration of $3,500,000.

On June 23, 2020, the Company completed the disposition of the NF Energy Group for $10 million. Management believes that the proceeds from the sale of the NF Energy Group and the sale of the convertible notes will provide the Company with sufficient funds to operate as a going concern for at least the next twelve months.

About BOQI International Medical Inc.

BOQI International Medical Inc. (formerly known as NF Energy Saving Corporation) (BIMI) was founded in 2006. In February 2019, the Board of Directors of the company was reorganized following efforts led by Mr. Yongquan Bi, the company’s new Chairman, with a focus on the health industry. The Company is now exclusively a healthcare products provider, offering a broad range of healthcare products and related services.

Safe Harbor Statement

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of Coronavirus (COVID-19), the demand for the Company’s products and the Company’s customers’ economic condition,  risk of operations in the People’s Republic of China, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission. Investors are urged to read the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2020 for further information about the Company’s financial results, liquidity and capital resources.

IR Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BIMI@dgipl.com


BOQI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
(FORMERLY KNOWN AS “NF ENERGY SAVING CORPORATION”)
CONDENSED CONSOLIDATED BALANCE SHEETS

 

March 31,

 

 

December 31,

 

 

2020

 

 

2019

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

Cash

$

175,865

 

 

$

36,363

 

Restricted cash

 

306

 

 

 

311

 

Accounts receivable, net

 

1,955,089

 

 

 

24,840

 

Advances to suppliers

 

1,021,318

 

 

 

1,252

 

Amount due from related parties

 

114,871

 

 

 

1,350

 

Inventories, net

 

3,196,034

 

 

 

707,526

 

Prepayments and other receivables

 

382,303

 

 

 

59,333

 

Assets from discontinued operations

 

20,859,127

 

 

 

21,218,983

 

Total current assets

 

27,704,913

 

 

 

22,049,958

 

 

 

 

 

 

 

 

 

NON-CURRENT ASSETS

 

 

 

 

 

 

 

Deferred tax assets

 

252,857

 

 

 

-

 

Property, plant and equipment, net

 

735,473

 

 

 

38,641

 

Intangible assets, net

 

7,715,653

 

 

 

7,973,179

 

Goodwill

 

6,443,170

 

 

 

-

 

Total non-current assets

 

15,147,153

 

 

 

8,011,820

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

$

42,852,066

 

 

$

30,061,778

 

 

 

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

Short-term loans

$

832,733

 

 

$

-

 

Long-term loans due within one year

 

248,813

 

 

 

-

 

Convertible promissory note, net

 

402,341

 

 

 

107,383

 

Derivative liability

 

2,265,117

 

 

 

1,272,871

 

Accounts payable, trade

 

3,792,127

 

 

 

641,927

 

Advances from customers

 

1,162,480

 

 

 

67,975

 

Amount due to related parties

 

364,799

 

 

 

305,760

 

Taxes payable

 

352,246

 

 

 

861

 

Other payables and accrued liabilities

 

11,050,781

 

 

 

6,044,378

 

Liabilities from discontinued operations

 

13,241,724

 

 

 

13,108,038

 

Total current liabilities

 

33,713,161

 

 

 

21,549,193

 

 

 

 

 

 

 

 

 

Long-term loans - noncurrent portion

 

185,417

 

 

 

-

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

33,898,578

 

 

 

21,549,193

 

 

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 10,023,289 and 9,073,289 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

 

10,023

 

 

 

9,073

 

Additional paid-in capital

 

18,359,875

 

 

 

15,643,825

 

Statutory reserves

 

2,227,634

 

 

 

2,227,634

 

Accumulated deficit

 

(13,076,542

)

 

 

(10,881,667

)

Accumulated other comprehensive income

 

1,561,188

 

 

 

1,683,770

 

Total BOQI International Medical Inc.'s equity

 

9,082,178

 

 

 

8,682,635

 

 

 

 

 

 

 

 

 

NONCONTROLLING INTERESTS

 

(128,690

)

 

 

(170,050

)

 

 

 

 

 

 

 

 

Total equity

 

8,953,488

 

 

 

8,512,585

 

 

 

 

 

 

 

 

 

Total liabilities and equity

$

42,852,066

 

 

$

30,061,778

 

 

 

 

 

 

 

 

 

BOQI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
(FORMERLY KNOWN AS “NF ENERGY SAVING CORPORATION”)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)

 

For the Three Months Ended March 31,

 

 

2020

 

 

2019

 

 

 

 

 

 

 

REVENUES

$

426,898

 

 

$

-

 

 

 

 

 

 

 

 

 

COST OF REVENUES

 

461,782

 

 

 

-

 

 

 

 

 

 

 

 

 

GROSS LOSS

 

(34,884

)

 

 

-

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES:

 

 

 

 

 

 

 

Sales and marketing

 

118,746

 

 

 

-

 

General and administrative

 

1,632,707

 

 

 

122,614

 

Total operating expenses

 

1,751,453

 

 

 

122,614

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

(1,786,337

)

 

 

(122,614

)

 

 

 

 

 

 

 

 

OTHER EXPENSE, NET

 

 

 

 

 

 

 

Interest expense, net

 

(21,675

)

 

 

-

 

Other expense, net

 

(18,425

)

 

 

-

 

Total other expense, net

 

(40,100

)

 

 

-

 

 

 

 

 

 

 

 

 

LOSS BEFORE INCOME TAXES

 

(1,826,437

)

 

 

(122,614

)

 

 

 

 

 

 

 

 

PROVISION FOR INCOME TAXES

 

1,268

 

 

 

-

 

 

 

 

 

 

 

 

 

NET LOSS FROM CONTINUING OPERATIONS

 

(1,827,705

)

 

 

(122,614

)

 

 

 

 

 

 

 

 

DISCONTINUED OPERATIONS

 

 

 

 

 

 

 

Loss from operations of discontinued operations

 

(374,486

)

 

 

(419,834

)

 

 

 

 

 

 

 

 

NET LOSS

 

(2,202,191

)

 

 

(542,448

)

Less: net income (loss) attributable to noncontrolling interest

 

(7,316

)

 

 

25,146

 

NET LOSS ATTRIBUTABLE TO BOQI INTERNATIONAL MEDICAL INC.

$

(2,194,875

)

 

$

(567,594

)

 

 

 

 

 

 

 

 

COMPREHENSIVE LOSS

 

 

 

 

 

 

 

NET LOSS

$

(2,202,191

)

 

$

(542,448

)

OTHER COMPREHENSIVE INCOME (LOSS)

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

(120,201

)

 

 

231,927

 

TOTAL COMPREHENSIVE LOSS

 

(2,322,392

)

 

 

(310,521

)

Less: comprehensive income (loss) attributable to noncontrolling interest

 

(4,935

)

 

 

13,377

 

COMPREHENSIVE LOSS ATTRIBUTABLE TO BOQI INTERNATIONAL MEDICAL INC.

$

(2,317,457

)

 

$

(323,898

)

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

 

 

 

 

 

 

 

Basic and diluted

 

9,271,641

 

 

 

7,573,289

 

 

 

 

 

 

 

 

 

LOSS PER SHARE

 

 

 

 

 

 

 

Continuing operations - basic and diluted

$

(0.20

)

 

$

(0.02

)

Discontinued operations - basic and diluted

$

(0.04

)

 

$

(0.05

)

Net loss - basic and diluted

$

(0.24

)

 

$

(0.07

)

 

 

 

 

 

 

 

 

BOQI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
(FORMERLY KNOWN AS “NF ENERGY SAVING CORPORATION”)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

 

 

For the Three Months Ended March 31,

 

 

2020

 

2019

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss from continuing operations

 

$

(1,827,705

)

 

$

(122,614

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

261,920

 

 

 

-

 

Inventories impairments reserves

 

 

119,342

 

 

 

-

 

Reverse of allowance for doubtful accounts

 

 

(7,854

)

 

 

-

 

Amortization of discount of convertible promissory notes

 

 

294,958

 

 

 

-

 

Change in derivative liabilities

 

 

399,022

 

 

 

-

 

Change in operating assets and liabilities

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(101,128

)

 

 

-

 

Advances to suppliers

 

 

196,821

 

 

 

-

 

Inventories

 

 

(1,699,171

)

 

 

-

 

Prepayments and other receivables

 

 

(237,205

)

 

 

(121,500

)

Accounts payable, trade

 

 

1,894,663

 

 

 

-

 

Advances from customers

 

 

(248,329

)

 

 

110,785

 

Taxes payable

 

 

(52,560

)

 

 

-

 

Other payables and accrued liabilities

 

 

209,960

 

 

 

-

 

  Net cash used in operating activities from continuing operations

 

 

(797,266

)

 

 

(133,329

)

  Net cash provided by (used in) operating activities from discontinued operations

 

 

(1,513

)

 

 

501,241

 

    Net cash provided by (used in) operating activities

 

 

(798,779

)

 

 

367,912

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash received from acquisition of Guanzan Group

 

 

95,220

 

 

 

-

 

  Net cash provided by investing activities from continuing operations

 

 

95,220

 

 

 

-

 

  Net cash provided by investing activities from discontinued operations

 

 

-

 

 

 

-

 

    Net cash provided by investing activities

 

 

95,220

 

 

 

-

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Net proceeds from issuance of convertible promissory notes

 

 

593,224

 

 

 

-

 

Amount financed from related parties

 

 

250,112

 

 

 

133,329

 

  Net cash provided by financing activities from continuing operations

 

 

843,336

 

 

 

133,329

 

  Net cash used in financing activities from discontinued operations

 

 

-

 

 

 

(238,389

)

    Net cash provided by (used in) financing activities

 

 

843,336

 

 

 

(105,060

)

 

 

 

 

 

 

 

 

 

EFFECT OF EXCHANGE RATE ON CASH

 

 

(280

)

 

 

(262,852

)

 

 

 

 

 

 

 

 

 

INCREASE IN CASH

 

 

139,497

 

 

 

-

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS, beginning of period

 

 

36,674

 

 

 

-

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS, end of period

 

$

176,171

 

 

$

-

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid for income tax

 

$

-

 

 

$

-

 

Cash paid for interest expense, net of capitalized interest

 

$

-

 

 

$

88,264

 

 

 

 

 

 

 

 

 

 

NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Issuance of common shares for the equity acquisition of the Guanzan Group

 

$

2,717,000

 

 

$

-

 

Goodwill recognized from the equity acquisition of the Boqi Group

 

$

6,443,170

 

 

$

-

 

Outstanding payment for the equity acquisition of the Guanzan Group

 

$

4,414,119

 

 

$

-